- Home
- TWLO vs RPRX Comparison
TWLO vs RPRX Comparison
Compare TWLO & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWLO
- RPRX
- Stock Information
- Founded
- TWLO 2008
- RPRX 1996
- Country
- TWLO United States
- RPRX United States
- Employees
- TWLO N/A
- RPRX N/A
- Industry
- TWLO Computer Software: Prepackaged Software
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- TWLO Technology
- RPRX Health Care
- Exchange
- TWLO Nasdaq
- RPRX Nasdaq
- Market Cap
- TWLO 11.4B
- RPRX 11.7B
- IPO Year
- TWLO 2016
- RPRX 2020
- Fundamental
- Price
- TWLO $109.18
- RPRX $24.82
- Analyst Decision
- TWLO Buy
- RPRX Strong Buy
- Analyst Count
- TWLO 23
- RPRX 6
- Target Price
- TWLO $86.52
- RPRX $41.67
- AVG Volume (30 Days)
- TWLO 2.5M
- RPRX 3.1M
- Earning Date
- TWLO 02-12-2025
- RPRX 11-06-2024
- Dividend Yield
- TWLO N/A
- RPRX 3.37%
- EPS Growth
- TWLO N/A
- RPRX 518.56
- EPS
- TWLO N/A
- RPRX 2.55
- Revenue
- TWLO $4,339,151,000.00
- RPRX $2,266,003,000.00
- Revenue This Year
- TWLO $8.55
- RPRX $12.21
- Revenue Next Year
- TWLO $7.78
- RPRX $11.13
- P/E Ratio
- TWLO N/A
- RPRX $9.84
- Revenue Growth
- TWLO 5.77
- RPRX N/A
- 52 Week Low
- TWLO $52.51
- RPRX $24.70
- 52 Week High
- TWLO $116.43
- RPRX $31.66
- Technical
- Relative Strength Index (RSI)
- TWLO 62.60
- RPRX 34.39
- Support Level
- TWLO $108.13
- RPRX $24.70
- Resistance Level
- TWLO $116.43
- RPRX $25.28
- Average True Range (ATR)
- TWLO 3.33
- RPRX 0.44
- MACD
- TWLO -0.99
- RPRX -0.08
- Stochastic Oscillator
- TWLO 49.22
- RPRX 20.41
About TWLO Twilio Inc.
Twilio is a cloud-based communications platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.